cell therapy
BMS, Macmillan and 11 NHS Trusts publish report on cancer treatment prehabilitation
The report shows how prehabilitation can improve patient experience while alleviating capacity pressures
BMS acquires Orbital Therapeutics in $1.5bn deal
The deal includes several next-gen cell therapy candidates for autoimmune diseases
BMS, Takeda and Astex join AI training consortium
The initiative focuses on training AI models to aid in drug discovery and development
Adam Raff appointed as Orbital Therapeutics’ Senior Vice President, Clinical Development
Raff will lead Clinical and Regulatory Operations and will be part of the company’s executive leadership team
BMS receives NICE recommendation for immunotherapy combination in colorectal cancer
Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year
BMS receives FDA approval for immunotherapy combination in liver cancer
Around 42,240 people are expected to be diagnosed with liver cancer in the US this year
BMS granted FDA approval for immunotherapy combination in colorectal cancer
More than 154,000 cases of the disease are expected to be diagnosed in the US this year
BMS receives positive CHMP opinion for perioperative Opdivo regimen in lung cancer
Up to 55% of non-metastatic NSCLC patients will develop disease recurrence despite surgical resection
BMS granted EC approval for immunotherapy combination in liver cancer
More than 866,100 cases of the disease were diagnosed globally in 2022
Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis
Plaque psoriasis affects up to 90% of patients with the immune-mediated disease
BMS receives CHMP recommendation for Breyanzi in follicular lymphoma
The disease is the second most common form of non-Hodgkin lymphoma, accounting for up to 30% of cases
BMS receives CHMP recommendation for Opdivo/Yervoy combination in liver cancer
Hepatocellular carcinoma accounts for approximately 90% of all liver cancer cases globally